2008 Clinical Practice Guidelines - Canadian Diabetes Association

26. Nazaimoon WW, Sakinah O, Gapor A, et al. Effects of palm
olein tocopherol and tocotrienol on lipid peroxidation, lipid
profiles and glycemic control in non-insulin diabetes mellitus
patients. Nutr Res. 1996;16:1901-1911.
27. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin
supplementation on glycosylated hemoglobin
levels in patients with type 2 diabetes mellitus: a
placebo-controlled, double-blinded, randomized clinical trial.
Arch Intern Med. 2003;163:1587-1590.
28. Khan A, Safdar M, Ali Khan MM, et al. Cinnamon improves
glucose and lipids of people with type 2 diabetes. Diabetes Care.
2003;26:3215-3218.
29. Vanschoonbeek K,Thomassen BJ, Senden JM, et al. Cinnamon
supplementation does not improve glycemic control in postmenopausal
type 2 diabetes patients. J Nutr. 2006;136:977-980.
30. Mang B, Wolters M, Schmitt B, et al. Effects of a cinnamon
extract on plasma glucose, HbA, and serum lipids in diabetes
mellitus type 2. Eur J Clin Invest. 2006;36:340-344.
31. Blevins SM, Leyva MJ, Brown J, et al. Effect of cinnamon on
glucose and lipid levels in noninsulin-dependent type 2 diabetes.
Diabetes Care. 2007;30:2236-2237.
32. Rosales RF, Fernando RE. An inquiry to the hypoglycemic
action of Momodica charantia among type 2 diabetic patients.
Phil J Intern Med. 2001;39:213-216.
33. John AJ, Cherian R, Subhash HS, et al. Evaluation of the efficacy
of bitter gourd (momordica charantia) as an oral hypoglycemic
agent – a randomized controlled clinical trial. Indian
J Physiol Pharmacol. 2003;47:363-365.
34. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber
officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on
blood lipids, blood sugar and platelet aggregation in patients
with coronary artery disease. Prostaglandins Leukot Essent Fatty
Acids. 1997;56:379-384.
35. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum
(fenugreek) seeds on glycaemic control and insulin resistance
in type 2 diabetes mellitus: a double blind placebo controlled
study. J Assoc Physicians India. 2001;49:1057-1061.
36. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in
non-insulin-dependent diabetic patients. Diabetes Care. 1995;
18:1373-1375.
37. Vuksan V, Sung MK, Sievenpiper JL, et al. Korean red ginseng
(Panax ginseng) improves glucose and insulin regulation in wellcontrolled,
type 2 diabetes: results of a randomized, doubleblind,
placebo-controlled study of efficacy and safety. Nutr
Metab Cardiovasc Dis. 2008;18:46-56.
38. Althuis MD, Jordan NE, Ludington EA, et al. Glucose and
insulin responses to dietary chromium supplements: a metaanalysis.
Am J Clin Nutr. 2002;76:148-155.
39. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate
supplementation attenuates body weight gain and increases
insulin sensitivity in subjects with type 2 diabetes. Diabetes
Care. 2006;29:1826-1832.
40. Kleefstra N, Houweling ST, Jansman FG, et al. Chromium
treatment has no effect in patients with poorly controlled,
insulin-treated type 2 diabetes in an obese Western population:
a randomized, double-blind, placebo-controlled trial. Diabetes
Care. 2006;29:521-525.
41. Ghosh D, Bhattacharya B, Mukherjee B, et al. Role of chromium
supplementation in Indians with type 2 diabetes mellitus.
J Nutr Biochem. 2002;13:690-697.
42. Anderson RA, Roussel AM, Zouari N, et al. Potential antioxidant
effects of zinc and chromium supplementation in people
with type 2 diabetes mellitus. J Am Coll Nutr. 2001;20:212-
218.
43. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of
supplemental chromium improve glucose and insulin variables
in individuals with type 2 diabetes. Diabetes. 1997;46:1786-
1791.
44. Bahijiri SM, Mira SA, Mufti AM, et al.The effects of inorganic
chromium and brewer’s yeast supplementation on glucose tolerance,
serum lipids and drug dosage in individuals with type
2 diabetes. Saudi Med J. 2000;21:831-837.
45. Kleefstra N, Houweling ST, Bakker SJ, et al. Chromium treatment
has no effect in patients with type 2 diabetes in a Western
population: a randomized, double-blind, placebo-controlled
trial. Diabetes Care. 2007;30:1092-1096.
46. Balk EM,Tatsioni A, Lichtenstein AH, et al. Effect of chromium
supplementation on glucose metabolism and lipids: a systematic
review of randomized controlled trials. Diabetes Care.
2007;30:2154-2163.
47. Goldfine AB, Patti ME, Zuberi L, et al. Metabolic effects of
vanadyl sulfate in humans with non-insulin-dependent diabetes
mellitus: in vivo and in vitro studies. Metabolism. 2000;49:400-
410.
48. de Lordes Lima M, Cruz T, Pousada JC, et al. The effect of
magnesium supplementation in increasing doses on the control
of type 2 diabetes. Diabetes Care. 1998;21:682-686.
49. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium
supplementation improves insulin sensitivity and metabolic
control in type 2 diabetic subjects: a randomized double-blind
controlled trial. Diabetes Care. 2003;26:1147-1152.
50. de Valk HW, Verkaaik R, van Rijn HJ, et al. Oral magnesium
supplementation in insulin-requiring type 2 diabetic patients.
Diabet Med. 1998;15:503-507.
51. Eibl NL, Kopp HP, Nowak HR, et al. Hypomagnesemia in type
II diabetes: effect of a 3-month replacement therapy. Diabetes
Care. 1995;18:188-192.
52. Eriksson J, Kohvakka A. Magnesium and ascorbic acid supplementation
in diabetes mellitus. Ann Nutr Metab. 1995;39:217-
223.
53. Jacob S, Ruus P, Hermann R, et al. Oral administration of
RAC-alpha-lipoic acid modulates insulin sensitivity in patients
with type-2 diabetes mellitus: a placebo-controlled pilot trial.
Free Radic Biol Med. 1999;27:309-314.
54. Chen H, Karne RJ, Hall G, et al. High-dose oral vitamin C partially
replenishes vitamin C levels in patients with type 2 diabetes
and low vitamin C levels but does not improve
endothelial dysfunction or insulin resistance. Am J Physiol Heart
S93
MANAGEMENT